Recent Finacing
Recent Raise
Phenex develops small-molecule therapeutics targeting nuclear receptors—advancing an FXR program (Px-102 entering Phase IIa) and RORgt inhibitors for NASH/metabolic syndrome and autoimmune indications; based in Ludwigshafen, Germany.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
